Allogenic platelet concentrates from umbilical cord blood for knee osteoarthritis: preliminary results

Med Glas (Zenica). 2021 Feb 1;18(1):260-266. doi: 10.17392/1330-21.

Abstract

Aim To investigate the role of cordonal blood platelet-rich plasma (PRP) intra-articular injections for treating the patients with knee osteoarthritis in terms of procedure safety and clinical outcomes. Methods Twenty-five patients affected by knee osteoarthritis were enrolled and received one single intra-articular knee injection of umbilical cord PRP in a volume of 10 mL. A follow-up was investigated at time 0, 4, 8, 12 weeks and 6 months, evaluating clinical parameters and functional performances. Results No serious adverse events were identified. The paired ttest analysis showed a significant difference between baseline and each follow-up times for all clinical scales (p<0.05), with a significant improvement of clinical outcomes. Conclusion Allogeneic PRP can generate reliable therapeutic effect. The high content of tissue regenerative factors in cord blood platelets makes cordonal blood one of the ideal sources of PRP.

Keywords: allogenic; cordonal; osteoarthritis; platelet rich plasma.

MeSH terms

  • Fetal Blood
  • Humans
  • Hyaluronic Acid
  • Injections, Intra-Articular
  • Osteoarthritis, Knee* / therapy
  • Treatment Outcome

Substances

  • Hyaluronic Acid